Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | President | August 03, 2023 | August 07, 2023 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | April 30, 2026 | April 30, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director · President of R&D | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 03, 2023 · Filed August 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,774 |
Ending reported balance
After 2023-08-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-08-03 · Grant · Acquired 5,082 · Balance 22,972 F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 2 · 2023-08-03 · Grant · Acquired 3,859 · Balance 26,831 F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Row 3 · 2023-08-04 · Sale · Disposed 771 · Balance 26,060 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2023-08-04 · Sale · Disposed 1,869 · Balance 24,191 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2023-08-04 · Sale · Disposed 1,107 · Balance 23,084 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2023-08-04 · Sale · Disposed 101 · Balance 22,983 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2023-08-04 · Sale · Disposed 17 · Balance 22,966 F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2023-08-04 · Sale · Disposed 192 · Balance 22,774 F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 515 |
Reported balance
Holding disclosure · report date 2023-08-03 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 515 F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F2: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.
F3: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025.
Hemab Therapeutics Holdings, Inc.
Report date April 30, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2034-05-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on May 8, 2024. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2024 through January 1, 2027.
F2: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Scholar Rock Holding Corp
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 630,542 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 12,246 · Balance 630,542 F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 22:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 12,246 | $49.57 | $607,089.33 |
DisclosureSEC source: 0001104659-26-045583 · tm2612274-3_4seq1.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,542 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 58,521 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 23:13 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 47,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-013588 · tm266077-8_4seq1.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,788 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. F2 · balance_after: Consists of 45,767 shares of common stock, 147,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 00:56 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 20,438 | $42.70 | $872,702.60 |
DisclosureSEC source: 0001104659-26-004222 · tm263352-2_4seq1.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,767 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance-and time-based vesting conditions ("PSUs"). The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock. F2 · shares: (continued) The shares vested pursuant to awards that were granted on April 27, 2025. 50,000 shares subject to this PSU vested on January 12, 2026, with an additional 50,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four year, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. F3 · balance_after: 45,767 shares of common stock, 100,000 restricted stock units and 450,000 PSUs. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 1,620 | $30.01 | $48,611.66 |
DisclosureSEC source: 0001415889-25-015001 · form4-05302025_040504.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616,205 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs.. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.92 to $30.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 16,205 shares of common stock and 100,000 RSUs and 500,000 PSUs. The amount of PSUs reported herein represents the maximum number of shares of the Issuer's common stock that may be issued. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 5,130 | $29.63 | $152,000.36 |
DisclosureSEC source: 0001415889-25-015001 · form4-05302025_040504.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 617,825 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs.. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.92 to $29.81, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 17,825 shares of common stock and 100,000 RSUs and 500,000 Performance Stock Units (PSUs). The amount of PSUs reported herein represents the maximum number of shares of the Issuer's common stock that may be issued. Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:01 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 110,067 | $0.00 Strike: $32.91 | $0.00 |
DisclosureSEC source: 0001104659-25-045116 · tm2513936-3_4seq1.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,067 Underlying: Common Stock · 110,067 shares Expires 2035-05-02 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:08 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041460 · tm2513505-6_4seq1.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,955 F2 · shares: Represents performance based RSUs subject to performance- and time-based vesting conditions (the "PSUs"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration. Read SEC document |
| April 27, 2025 Filed Apr 29, 2025 22:08 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-041460 · tm2513505-6_4seq1.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,955 F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:32 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001415889-24-018649 · form4-07012024_090729.xml · derivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-27 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:32 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018649 · form4-07012024_090729.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,955 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 9,455 shares of common stock and 13,500 RSUs. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:22 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000054 · wk-form4_1717446166.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 192 | $189.31 | $36,347.52 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,774 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 17 | $188.40 | $3,202.80 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,966 F8 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 101 | $187.37 | $18,924.37 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,983 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,107 | $186.39 | $206,333.73 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,084 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,869 | $185.54 | $346,774.26 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,191 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 771 | $184.70 | $142,403.70 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,060 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,831 F2 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000076 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,972 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 23:11 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001415889-23-010207 · form4-06222023_110609.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001415889-23-009234 · form4-06052023_040619.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 168 | $197.08 | $33,109.44 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,890 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 104 | $195.65 | $20,347.60 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,058 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,013 | $194.94 | $197,474.22 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,162 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 910 | $193.93 | $176,476.30 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,175 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 197 | $193.18 | $38,056.46 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,085 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 21:54 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000045 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,282 F1 · kind: On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS). Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,986 | $0.00 Strike: $190.01 | $0.00 |
DisclosureSEC source: 0001735276-23-000030 · edgardoc.xml · derivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,986 Underlying: Common Stock · 11,986 shares Expires 2033-02-27 F4 · shares: Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 5,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000030 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,790 Underlying: Common Stock · 5,790 shares Expires 2026-02-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · shares: Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 11,579 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest. F3 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 30,913 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · derivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,913 shares Expires 2023-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F8 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,302 | $217.05 | $933,749.10 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,970 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $216.96 to $217.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 19,447 | $216.38 | $4,207,941.86 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,272 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $215.89 to $216.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,279 | $215.59 | $2,216,049.61 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,719 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $214.88 to $215.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,307 | $214.28 | $494,343.96 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,998 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $213.72 to $214.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,709 | $213.13 | $364,239.17 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,305 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $212.71 to $213.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 30,913 | $63.00 | $1,947,519.00 |
DisclosureSEC source: 0001735276-23-000009 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,124 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · derivative · entry 8 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,876 Underlying: Common Stock · 1,124 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,587 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · derivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,913 Underlying: Common Stock · 1,587 shares Expires 2023-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,368 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · derivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,368 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 1,324 | $226.20 | $299,488.80 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,101 Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,368 | $42.22 | $99,976.96 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,587 | $63.00 | $99,981.00 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,124 | $88.95 | $99,979.80 |
DisclosureSEC source: 0001735276-22-000078 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 198 | $210.75 | $41,728.50 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 7 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,346 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 180 | $210.66 | $37,918.80 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 6 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,544 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 195 | $210.22 | $40,992.90 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 5 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,724 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 5,479 | $189.76 | $1,039,695.04 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 4 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,919 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,398 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,539 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,298 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.